Scolaris Content Display Scolaris Content Display

Melatonin for tinnitus

Esta versión no es la más reciente

Contraer todo Desplegar todo

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess the effectiveness of melatonin for the treatment of subjective idiopathic tinnitus.

Background

The following paragraphs andDescription of the conditionare based on the Cochrane review 'Amplification with hearing aids for patients with tinnitus and co‐existing hearing loss' and reproduced with permission (Hoare 2014).

Tinnitus is defined as the perception of sound in the absence of an external source (Jastreboff 2004). It is typically described by those who experience it as a ringing, hissing, buzzing or whooshing sound and is thought to result from abnormal neural activity at some point or points in the auditory pathway, which is erroneously interpreted by the brain as sound. Tinnitus can be either objective or subjective. Objective tinnitus refers to the perception of sound that can also be heard by the examiner and is usually due to blood flow or muscle movement (Eggermont 2010). Most commonly, however, tinnitus is subjective; the sound is only heard by the person experiencing it and no source of the sound is identified (Jastreboff 1988). Subjective tinnitus affects 10% of the general population, increasing to as many as 30% of adults over the age of 50 years (Davis 2000; Møller 2000). It can be experienced acutely, recovering spontaneously within minutes to weeks, but is considered chronic and unlikely to resolve spontaneously when experienced for six months or more (Hahn 2008; Rief 2005). In England alone there are an estimated ¾ million GP consultations every year where the primary complaint is tinnitus (El‐Shunnar 2011), equating to a major burden on healthcare services. For many people tinnitus is persistent and troublesome, and has disabling effects such as insomnia, difficulty concentrating, difficulties in communication and social interaction, and negative emotional responses such as anxiety and depression (Andersson 2009; Crönlein 2007; Marciano 2003). In approximately 90% of cases, chronic tinnitus is co‐morbid with some degree of hearing loss, which may confound these disabling effects (Fowler 1944; Sanchez 2002). An important implication in clinical research therefore is that outcome measures of benefit need to distinguish benefits specific to improved hearing from those specific to tinnitus.

Description of the condition

Diagnosis and clinical management of tinnitus

There is no standard procedure for the diagnosis or management of tinnitus. There are, however, recent guidelines for doing so from the UK Department of Health (Department of Health 2009), and the international organisation, the Tinnitus Research Initiative (Biesinger 2011). Both guidelines recommend that tinnitus and its impact on the person are assessed using validated questionnaire measures of severity, quality of life, depression or anxiety. Psychoacoustic measures of tinnitus (pitch, loudness, minimum masking level) are also recommended. Although these do not correlate well with tinnitus severity (Hiller 2006), they can prove useful in patient counselling (Henry 2004), or to demonstrate stability of the tinnitus percept over time (Department of Health 2009). Recommended clinical management strategies include directive counselling, relaxation therapy, tinnitus retraining therapy (TRT), cognitive behavioural therapy (CBT), sound enrichment using ear‐level sound generators or hearing aids, and drug therapies to manage co‐morbid symptoms such as insomnia, anxiety or depression (Department of Health 2009). All show variable efficacy and have little known risk of adverse effects (Hoare 2011; Hobson 2010; Martinez‐Devesa 2010; Phillips 2010). Where there is a hearing loss and tinnitus, the most common recommendation is to fit a hearing aid, although this practice also varies according to clinical experience and anecdotal evidence. For example, there is a clearly divided opinion among clinicians as to whether or not a hearing aid should be recommended to someone with a mild or higher‐frequency hearing loss that ordinarily might go unaided (Hoare 2012).

Pathophysiology

Most people with chronic tinnitus have some degree of hearing loss (Ratnayake 2009), and the prevalence of tinnitus increases with increased hearing loss (Han 2009; Martines 2010). The varying theories of tinnitus generation involve either changes in function or activity of the peripheral (cochlea and auditory nerve) or central auditory nervous systems (Henry 2005). Theories involving the peripheral systems include the discordant damage theory, which predicts that the loss of outer hair cell (OHC) function where inner hair cell (IHC) function is left intact leads to a release from inhibition of IHC and aberrant activity (typically hyperactivity) in the auditory nerve (Jastreboff 1990). Such aberrant auditory nerve activity can also have a biochemical basis, resulting from excitotoxicity or stress‐induced enhancement of IHC glutamate release with upregulation of N‐methyl‐D‐aspartate (NMDA) receptors (Guitton 2003; Sahley 2001). In the central auditory system, structures implicated as possible sites of tinnitus generation include the dorsal cochlear nucleus (Middleton 2011; Pilati 2012), the inferior colliculus (Dong 2010; Mulders 2010), and the auditory and non‐auditory cortex (discussed further below). There is a strong rationale to say that it is a direct consequence of maladaptive neuroplastic responses to hearing loss (Møller 2000; Mühlnickel 1998). This process is triggered by sensory deafferentation and a release from lateral inhibition in the central auditory system allowing irregular spontaneous hyperactivity within the central neuronal networks involved in sound processing (Eggermont 2004; Rauschecker 1999; Seki 2003). As a consequence of this hyperactivity, a further physiological change noted in tinnitus patients is an increased spontaneous synchronous activity occurring at the cortical level, measurable using electroencephalography (EEG) or magnetoencephalography (MEG) (Dietrich 2001; Tass 2012; Weisz 2005).

Another physiological change thought to be involved in tinnitus generation is a process of functional reorganisation, which amounts to a change in the response properties of neurons within the primary auditory cortex to external sounds. This effect is well demonstrated physiologically in animal models of hearing loss (Engineer 2011; Noreña 2005). Evidence in humans, however, is limited to behavioural evidence of cortical reorganisation after hearing loss demonstrating improved frequency discrimination ability at the audiometric edge (Kluk 2006; McDermott 1998; Moore 2009; Thai‐Van 2002; Thai‐Van 2003), although Buss 1998 did not find this effect. For comprehensive reviews of these physiological models, see Adjamian 2009 and Noreña 2011. It is also proposed that spontaneous hyperactivity could cause an increase in sensitivity or 'gain' at the level of the cortex, whereby neural sensitivity adapts to the reduced sensory inputs, in effect stabilising mean firing and neural coding efficiency (Noreña 2011; Schaette 2006; Schaette 2011). However, such adaptive changes would be achieved at the cost of amplifying 'neural noise' due to the overall increase in sensitivity, ultimately resulting in the generation of tinnitus.

Increasingly, non‐auditory areas of the brain, particularly areas associated with emotional processing, are also implicated in the maintenance of bothersome tinnitus (Rauschecker 2010; Vanneste 2012). Vanneste 2012 recently described tinnitus as "an emergent property of multiple parallel dynamically changing and partially overlapping sub‐networks", implicating the involvement of many structures of the brain more associated with memory and emotional processing in tinnitus generation. Identification of the structural components of individual neural networks responsible for either tinnitus generation or tinnitus intrusiveness, which are independent of those for hearing loss, remains open to future research, however (Melcher 2013). One further complication in understanding the pathophysiology of tinnitus is that not all people with hearing loss have tinnitus, and not all people with tinnitus have a clinically significant hearing loss. There are possible explanations for this, however. For example, König 2006 found that the maximum slope within audiograms was higher in people with tinnitus than in people with hearing loss who do not have tinnitus, despite their 'non‐tinnitus' group having the greater mean hearing loss. This suggests that a contrast in sensory inputs between regions of normal and elevated threshold may be more likely to result in tinnitus.

Description of the intervention

The neurohormone melatonin (N‐acetyl‐5‐methoxytryptamine) can be administered as a 'supplement' and it has shown some effect in patients with various sleep disorders (Hoang 2007; Hurtuk 2011; Lopez‐Gonzalez 2007; Piccirillo 2007). Melatonin is an endogenously produced indoleamine neurohormone, secreted by the pineal gland in vertebrates (Cesarani 2005; Lopez‐Gonzalez 2007; Pirodda 2010; Reiter 2011). It is known to be produced by a variety of cells/tissues including the cochlea and is reported to regulate inner ear immunity (Pirodda 2010; Reiter 2011; Salvi 2009). It has been suggested that melatonin administered at a dose of 3 mg per day may improve patients' tinnitus symptoms, using outcome measures such as the Tinnitus Handicap Inventory (THI), tinnitus loudness and visual analogue scales (VAS) (range 0 to 10) (Hurtuk 2011; Reiter 2011; Rosenberg 1998).

How the intervention might work

Depression, insomnia and sleep disturbance are major complaints in patients with tinnitus (Hurtuk 2011; Lopez‐Gonzalez 2007; Megwalu 2006; Pyykkö 2008; Pirodda 2010; Rosenberg 1998). Melatonin has been proposed as a treatment for tinnitus because of its effects on sleep (it synchronises circadian and circannual rhythms) and because of its vasoactive/antioxidant properties. Several physio‐pathological effects support the consideration of melatonin for use in the treatment of tinnitus. It has been reported to have antidepressive effects, which could indirectly act on tinnitus. Melatonin also has an effect on labyrinthine perfusion by inducing a more steady haemodynamic condition and it has been reported to have a protective mechanism against an exaggerated sympathetic drive, because of its effects on the central nervous system (Hurtuk 2011; Pirodda 2010). A small number of randomised controlled trials have been undertaken, showing possible benefit to sleep in tinnitus patients (Rosenberg 1998; Salvi 2009).

Why it is important to do this review

Tinnitus is a common symptom and is associated with significant morbidity in certain patient groups. Melatonin‐based treatments are employed to treat patients with tinnitus, but to date the efficacy of these treatments has not been formally assessed in a systematic review. Side effects of melatonin are rare and a systematic review would help to clarify whether this is a useful therapy.

Objectives

To assess the effectiveness of melatonin for the treatment of subjective idiopathic tinnitus.

Methods

Criteria for considering studies for this review

Types of studies

Randomised controlled trials (RCTs).

Types of participants

Adults with chronic subjective tinnitus.

Types of interventions

Melatonin treatment versus placebo only. We will exclude studies that compare melatonin with another active treatment, to avoid confounding factors.

Types of outcome measures

Primary outcomes

  • Improvement in tinnitus severity and disability, measured by a validated tinnitus specific questionnaire. Acceptable tinnitus questionnaires are listed in Table 1.

    Open in table viewer
    Table 1. Tinnitus questionnaires

    Title

    No. of items/factors

    Psychometrics

    Tinnitus Questionnaire (Hallam 1996)

    52 items, 5 factors

    a = 0.91 for total scale; for subscales a = 0.76 to a = 0.94

    Tinnitus Handicap Questionnaire (Kuk 1990)

    27 items, 3 factors

    a = 0.93 for total scale

    Tinnitus Severity Scale (Sweetow 1990)

    15 items

    Alpha not reported

    Tinnitus Reaction Questionnaire (Wilson 1991)

    26 items, 4 factors

    a = 0.96 and a test‐retest correlation of r = 0.88

    Subjective Tinnitus Severity Scale (Halford 1991)

    16 items

    a = 0.84

    Tinnitus Handicap/Support Scale (Erlandsson 1992)

    28 items, 3 factors

    Alpha not reported

    Tinnitus Handicap Inventory (Newman 1996)

    25 items, 3 scales

    a = 0.93 for total scale

    Tinnitus Coping Strategy Questionnaire (Henry 1995)

    33

    a = 0.88

    Tinnitus Coping Style Questionnaire (Budd 1995)

    40

    Tinnitus Cognitions Questionnaire (Wilson 1998)

    Tinnitus Severity Index (Meikle 1995)

    Tinnitus Acceptance Questionnaire (Westin 2008)

  • Adverse events.

Secondary outcomes

  • Improvement in tinnitus perception, loudness or intensity (specific auditory disease evaluation).

  • Improvement/change in depressive symptoms or in depression scores.

  • Improvement/change in global well being.

  • Reduced sleep disruption, measured by a validated sleep questionnaire.

Search methods for identification of studies

We will conduct systematic searches for randomised controlled trials and controlled clinical trials. There will be no language, publication year or publication status restrictions. We may contact original authors for clarification and further data if trial reports are unclear and we will arrange translations of papers where necessary.

Electronic searches

We will identify published, unpublished and ongoing studies by searching the following databases from their inception: the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL, current issue); PubMed; EMBASE; CINAHL; LILACS; KoreaMed; IndMed; PakMediNet; CAB Abstracts; Web of Science; AMED; PsycINFO; ISRCTN; ClinicalTrials.gov; ICTRP; Google Scholar and Google.

We will model subject strategies for databases on the search strategy designed for CENTRAL (Appendix 1). Where appropriate, we will combine subject strategies with adaptations of the highly sensitive search strategy designed by The Cochrane Collaboration for identifying randomised controlled trials and controlled clinical trials (as described in theCochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011)).

Searching other resources

We will scan the reference lists of identified publications for additional trials and contact trial authors if necessary. In addition, we will search PubMed, TRIPdatabase, The Cochrane Library and Google to retrieve existing systematic reviews relevant to this systematic review, so that we can scan their reference lists for additional trials. We will search for conference abstracts using the Cochrane Ear, Nose and Throat Disorders Group Trials Register and EMBASE.

Data collection and analysis

Selection of studies

Two review authors will independently screen the titles/abstracts initially, to identify studies which meet the criteria outlined above. We will then obtain full texts for potentially relevant studies. We will resolve any differences of opinion by discussion.

Data extraction and management

We will extract data onto standardised, pre‐piloted forms. We will contact study authors if necessary for clarification. If there is disagreement we will resolve this by discussion.

We will extract data related to the inclusion and exclusion criteria, risk of bias and outcome measures.

Assessment of risk of bias in included studies

The authors will undertake assessment of the risk of bias of the included trials independently, with the following taken into consideration, as guided by theCochrane Handbook for Systematic Reviews of Interventions (Handbook 2011):

  • sequence generation;

  • allocation concealment;

  • blinding;

  • incomplete outcome data;

  • selective outcome reporting; and

  • other sources of bias.

We will use the Cochrane 'Risk of bias' tool in RevMan 5.3 (RevMan 2014), which involves describing each of these domains as reported in the trial and then assigning a judgement about the adequacy of each entry: 'low', 'high' or 'unclear' risk of bias.

Dealing with missing data

We will contact study authors and correlate any missing data. We will not make any assumptions if data cannot be obtained.

Assessment of heterogeneity

We will perform statistical analysis using Review Manager 5.3 (RevMan 2014). We will use both the Chi2 test and the I2 statistic to assess statistical heterogeneity formally. We hope that we will be able to pool data in meta‐analysis, however we will only perform this in the absence of clear clinical and statistical heterogeneity. If it is not possible to pool data, we will present a narrative synthesis of the included studies.

Data synthesis

Study outcomes are likely to be measured in a variety of ways using continuous, discrete and categorical variables. We may dichotomise data if appropriate. We will seek statistical advice to determine the best way of presenting and summarising the data.

Data analysis will be by intention‐to‐treat. For dichotomous outcomes we will calculate a risk ratio (RR) with 95% confidence interval (CI).

We will use the mean difference (MD) or standardised mean difference (SMD) for continuous outcomes, as appropriate, with 95% CIs.

Subgroup analysis and investigation of heterogeneity

If possible, we will compare the effect of different doses of melatonin. If sufficient data are available we will carry out subgroup analysis, grouping patients by duration and severity of disease.

Sensitivity analysis

We will use study risk of bias in a sensitivity analysis.

Table 1. Tinnitus questionnaires

Title

No. of items/factors

Psychometrics

Tinnitus Questionnaire (Hallam 1996)

52 items, 5 factors

a = 0.91 for total scale; for subscales a = 0.76 to a = 0.94

Tinnitus Handicap Questionnaire (Kuk 1990)

27 items, 3 factors

a = 0.93 for total scale

Tinnitus Severity Scale (Sweetow 1990)

15 items

Alpha not reported

Tinnitus Reaction Questionnaire (Wilson 1991)

26 items, 4 factors

a = 0.96 and a test‐retest correlation of r = 0.88

Subjective Tinnitus Severity Scale (Halford 1991)

16 items

a = 0.84

Tinnitus Handicap/Support Scale (Erlandsson 1992)

28 items, 3 factors

Alpha not reported

Tinnitus Handicap Inventory (Newman 1996)

25 items, 3 scales

a = 0.93 for total scale

Tinnitus Coping Strategy Questionnaire (Henry 1995)

33

a = 0.88

Tinnitus Coping Style Questionnaire (Budd 1995)

40

Tinnitus Cognitions Questionnaire (Wilson 1998)

Tinnitus Severity Index (Meikle 1995)

Tinnitus Acceptance Questionnaire (Westin 2008)

Figuras y tablas -
Table 1. Tinnitus questionnaires